Although new salicylates are now available for the treatment of ulcerative colitis, sulphasazaline still has an important therapeutic role. The role of salicylates in Crohn's disease is limited to the mild activity phase; further data are required to clarify its role in maintenance on remission. New steroids are a real alternative to traditional steroids in active ulcerative colitis and Crohn's disease. 
I
n the 1930s, a Swedish doctor, Svartz, 1 in the effort to obtain a new drug for rheumatoid arthritis, combined a salicylate (5-aminosalicylic acid, 5-ASA) with a sulphonamide (sulphapiridine, SP) in a molecule named salicylazosulphapiridine (sulphasazaline, SSP). The first results in rheumatoid arthritis were not impressive, but when she used this molecule in patients with arthritis and ulcerative colitis (UC), she had encouraging results. The introduction of SSP in the treatment of UC opened two new therapeutic options in this disease: a valid alternative to glucocorticosteroid (GCS) treatment in active disease; and the concept of maintenance treatment. In order to identify the active therapeutic moiety of SSP, Azad Khan 2 compared enemas of SSP, SP, or 5-ASA in the treatment of patients with active UC. It was found that pronounced histological improvement occurred equally frequently with SSP and 5-ASA, whereas SP had virtually no effect. These results suggested that SSP has the capacity to reach the colon intact and then to liberate 5-ASA, which is the active agent. The SP appeared to act simply as a carrier which permits this to happen.
Despite the proven efficacy of this drug, the high incidence of dose related and non-dose related side effects, occurring in up to 45% of patients, limit its usefulness. The recognition that most of the side effects were related to the SP component and that 5-ASA was the active moiety, led pharmaceutical companies to prepare a wide range of 5-ASA preparations able to reach the lower part of the gastrointestinal tract. In the past two decades, the major efforts were employed to find alternative 5-ASA delivery systems. This aim was achieved in two ways: by a coating that dissolves at alkaline pH (Eudragit S, pH >7; Eudragit L, pH >6; microsphere formulation enveloped with ethylcellulose), which is the pH present in the terminal ileum; or by substitution of SP with another carrier that allows it to reach the colon and to deliver the active moiety, following splitting of the diazo bond by bacteria.
EFFICACY AND TOLERANCE OF THE NEW PREPARATIONS
Oral aminosalicylate therapy is, today, the "first line" therapy in patients with mild to moderate extensive UC; in several countries, these have completely replaced SSP. Up to 80% of treated patients show a clinical response with 2-4.8 g/day mesalamine. However, these products are more expensive and have been shown to cause adverse effects in some patients. A meta-analysis 3 of prospective, randomised, double blind, placebo or SSP controlled trials showed that 5-ASA was more effective than placebo in the treatment of active disease and in maintenance of remission. A trend in favour of a slight benefit for the newer 5-ASA preparations over SSP in active disease was observed. There is only a modest difference in maintenance of remission between the two treatments.
The response rate of SSP in clinical trials was dose related. The new 5-ASA preparations required approximately 40% of the dose compared with the parent compound; a corresponding dose of 5-ASA up to 10 g of SSP was commonly prescribed. An additional advantage of mesalazine compared to SSP was the absence of dose related intolerance or toxicity, which limited the clinical utility of SSP at the highest doses. With rare exceptions, most patients intolerant to SSP will tolerate an oral or rectal form of aminosalicylates. The overall incidence of adverse events and withdrawals in the trials was significantly more frequent with SSP than with 5-ASA. This difference was not found in maintenance of remission, suggesting that these patients tolerate SSP better at these low doses than do patients with active disease.
These observations suggest that SSP is an effective and cheaper therapy that could be used in a subgroup of tolerant patients.
There have been too few clinical trials to distinguish between mesalazine formulations. Recently, however, balsalazide, a prodrug in which 5-ASA is linked with a diazo bond to an inert and biologically inactive carrier molecule, was compared with mesalazine in patients with active UC. 4 After 8 and 12 weeks of treatment, 54% and 62% of patients in the balsalazide group were in remission, compared to 22% and 37% in the mesalazine group, respectively. Moreover, balsalazide was more tolerable than mesalazine, causing fewer side effects. Similar results were obtained in another study that compared balsalazine to mesalazine in the maintenance of remission in UC patients. 5 There were no differences in tolerance and incidence of side effects between the two groups.
The good tolerance of 5-ASA formulations contributed to inclusion of the maintenance treatment in practical guidelines. This chronic treatment changed the natural history of the disease; there was the lowest incidence of severe relapse in the past decade.
The major innovation in the treatment of UC was the introduction of topical formulations. Rectally administered preparations of 5-ASA should be the preferred treatment for mild to moderate left sided or distal UC. These preparations include suppositories, foams, and liquid enemas, which differ in their physicochemical properties and potential for proximal spread. Administering 5-ASA rectally offers the advantage of delivering the treatment directly to the site of maximum inflammation, while potentially minimising the frequency of systemic side effects.
Dose-response effects of topical therapy have been studied in several controlled trials which confirm the absence of an initial dose-response between 1 and 4 g/day. 6 Marshall and Irvine, 7 in a meta-analysis, showed that rectal 5-ASA was superior to placebo and rectal GCS in the treatment of active left sided UC. Several studies showed that topical 5-ASA (suppositories or enemas) was superior to oral mesalazine in the treatment of this disease, with good tolerance and patient compliance. Combination treatment with oral and rectal mesalazine is more effective than a single agent and is useful in patients with refractory disease.
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Topical 5-ASA also has an important role in maintenance of remission. While dose ranging trials for topical therapy have not been performed, dose interval trials have shown a dose interval benefit between alternate night dosing or every third night dosing.
THE ROLE OF SALICYLATES IN CD
The role of 5-ASA in active CD was established by a large placebo controlled American trial to show the efficacy of mesalazine at 4 g/day; this led to the clinical use of mesalamine for mild to moderate CD. Because of their low toxicity and good tolerability, aminosalicylates were a promising choice in maintenance of medical and surgical induced remission in CD.
The results of studies in maintenance treatment are conflicting; in a meta-analysis, Cammà and colleagues found that mesalazine only reduces the risk of symptomatic relapse in patients with surgically induced remission, ileitis, and prolonged disease duration. 18 This conclusion, however, was recently challenged.
The role of mesalazine in the prevention of post-surgical relapse, seems to be well established. Caprilli and colleagues, 19 in 110 postoperative patients, found that Asacol (5-aminosalicylic acid) 2.4 g/day reduced the clinical (from 41% to 18%) and endoscopic (from 85% to 52%) recurrence rates at 24 months. This was not, however, a double blind study (the control group did not receive placebo); furthermore, the clinical recurrence rates in the control group were rather low.
McLeod and colleagues 20 treated 163 patients who had undergone surgical resection with mesalazine 3 g/day. After three years follow up, 31% of patients in the mesalazine group had a clinical recurrence compared with 41% in the control group (p = 0.031).
Gendre and colleagues 21 reported a muticentre French study of 161 patients given 2 g/day Pentasa (mesalamine) or placebo. They stratified patients into groups of presumed high risk for early relapse or lower risk. Pentasa reduced relapse rate in the high risk group compared with placebo (29% versus 45%). A Canadian study 22 of 293 patients did not confirm these conclusions, but did find that Pentasa 3 g/day reduced clinical relapse rates overall compared with placebo (25% versus 36%, a result that did not quite reach statistical significance) and somewhat prolonged the asymptomatic interval. Brignola and colleagues 23 treated 87 patients with either 3 g/day Pentasa or placebo for one year; the frequency of severe endoscopic recurrence was 24% in the mesalazine group and 56% in the placebo group, but the rate of clinical symptomatic recurrence was similar.
Because of the mixed results and trends towards improvement of mesalazine reported by some studies, meta-analysis has been used to try to clarify the issue. Several different drug regimens were compared and the patient populations were not homogeneous. Cammà et al found an overall decrease in relapse rate of 13.1% with mesalazine, especially after surgical resection, for ileal disease and in those with prolonged disease. 18 Recently, Lochs and colleagues 24 published a randomised, double blind, placebo controlled study on mesalazine 4 g/day in the prevention of clinical recurrence. A total of 318 patients were studied; mesalazine failed to improve remission rate after 18 months of treatment. Statistical significance was reached only in the subgroup with isolated ileal disease.
Cammà et al revised their meta-analysis to include this study, and determined that the risk reduction was 10% with mesalazine, corresponding to a number needed to treat of 10.
Sutherland excluded the Caprilli et al study (which reported the greatest benefit for 5-ASA, but was not blinded and therefore may have been subject to bias) from the above meta-analysis, and found an overall risk difference of 8%; the NNT (number of patients needed to treat) to prevent one relapse was 12. 25 26 It is therefore difficult to recommend mesalazine in the postoperative setting: the improvement in recurrence rate is small and, even though it is a safe agent, the cost ot its routine use would be considerable.
GLUCOCORTICOSTEROIDS IN IBD
Several uncontrolled trials between 1950 and 1970 showed that GCS and ACTH are helpful in the treatment of Crohn's disease (CD). In 1979 the National Cooperative Crohn's Disease Study 27 showed in a randomised, prospective, double blind, placebo controlled trial that prednisone 0.25-0.75 mg/kg/day (according to the Crohn's Disease Activity Index) led to an improvement in 60% of treated patients compared to 30% in the placebo group. Moreover, treatment with prednisone was superior to sulphasalazine (SSP) and azathioprine (AZA). Subsequently, the European Crohn's Disease Study 28 published the results obtained with 6-methylprednisolone 48 mg/day (fixed dose for all patients) for seven days and weekly tapering to 8 mg/day. Eighty three per cent of the patients treated with 6-methylprednisolone were in remission before week 18 compared with 50% in the SSP group and 38% in the placebo group. Even better results were obtained in GETAID's studies, where prednisone 1 mg/kg/day was administered for 3-7 weeks and then tapered in steps of 5-10 mg per 10 days to complete discontinuation. 29 This schedule is able to induce clinical remission in more than 90% of patients. The length of GCS treatment, moreover, does not seem to influence the remission rate after cessation of treatment (85% after 7 weeks versus 87% after 15 weeks). 30 Two open questions on GCS treatment concern steroid dependence (36% after the first steroid course in Copenhagen county) 31 and steroid related side effects (table 1) .
THE NEW STEROIDS
Non-systemic GCS have been used for several years for the inhalation treatment of asthma and very few steroid related side effects have been found. Budesonide and beclomethasone dipropionate, and to a lesser extent, fluticasone propionate, tixocortol pivalate, and prednisolone metasulphobenzoate have been tested in patients with IBD.
Budesonide controlled ileal release (CIR)
Budesonide is a non-halogenated GCS, structurally related to 16α-hydroxyprednisolone. The drug is a 1:1 mixture of two epimers, 22R and 22S. Its chemical name is 16α-butylidenedioxypregna-1,4-diene-11β,21-diol-3,20-dione. Budesonide CIR capsules consist of hard gelatine filled with enteric coated spherical granules containing budesonide. In addition to being practically insoluble in gastric juice, the granules have extended release properties adjusted to release budesonide during passage through the small bowel. The pharmacokinetic profile of budesonide favours a high topical efficacy, because of rapid uptake by mucosal tissue, and high GCS affinity, while minimising the risk of systemic effects as a result of efficient hepatic inactivation. These features help to ensure that treatment with budesonide is well tolerated and that patient compliance is maintained. Oral administration of budesonide results in rapid and complete absorption. However, because of the extensive first pass hepatic biotransformation, systemic bioavailability following an oral dose of plain budesonde is low, approximately 10%. Furthermore, the principal metabolites of budesonide are of low potency, displayng less than 1% of the GCS receptor affinity of their parent compound. The metabolites are removed by urinary excretion. 32 33 Rectal preparations have similar characteristics to those of oral preparations.
Beclomethasone dipropionate (BDP)
The chemical name of BDP is 9α-cloro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,2-dione-17,21-dipropionate. The pharmacokinetic profile of BDP favours a high topical efficacy, as a result of rapid uptake by mucosal tissue, and high GCS affinity, while minimising the risk of systemic effects as a result of efficient hepatic inactivation. The metabolite is removed by urinary and biliary excretion.
Results in controlled studies
In UC, new steroids have mainly been tested as rectal preparations in patients with left sided or distal colitis. All trials showed that efficacy of budesonide and beclomethasone is comparable to or superior to that of prednisone and comparable to or slightly inferior to that of 5-ASA. Combination treatment with 5-ASA and beclomethasone is superior to either drug alone.
Budesonide CIR has been used in patients with active CD with good clinical results. 34 35 Greenberg and colleagues, 35 in a randomised, placebo controlled, dose finding study, tested three different doses of budesonide (3, 9, and 15 mg/day) in patients with active CD. After eight weeks of treatment, remission occurred in 51% of patients in the group receiving 9 mg, 43% in patients receiving 15 mg, and 33% in patients receiving 3 mg, compared with 20% of those receiving placebo. Rutgeerts and colleagues 36 compared budesonide 9 mg/day with prednisolone 40 mg/day in the treatment of patients with mild to moderate active CD. At 10 weeks, 53% of patients treated with budesonide were in remission compared with 66% of those treated with prednisolone (p = 0.12). These data were confirmed by Campieri and colleagues, 37 who tested budesonide 9 mg once daily with budesonide 4.5 mg twice daily or prednisolone 40 mg/day in the treatment of patients with mild to moderate active CD. After eight weeks of treatment, remission occurred in 60% of patients treated with budesonide 9 mg once daily or prednisolone and in 42% of those treated with budesonide twice daily (p = 0.062). Budesonide CIR 9 mg/day was compared with mesalazine 4 g/day in mild to moderate active CD by Thomsen et al. After 16 weeks, 62% of patients treated with budesonide were in remission compared to 36% of those treated with mesalazine (p < 0.001). 38 In maintenance therapy, budesonide 6 mg/day has been shown to be significantly more efficacious than placebo in prolonging time to relapse in CD. Löfberg and colleagues, 39 in a placebo controlled one year study, compared the efficacy of budesonide 3 and 6 mg/day and placebo for maintenance of remission in patients with ileal and ileocaecal CD. The median time to relapse was 258 days in the 6 mg group, 139 days in the 3 mg group, and 92 days in the placebo group (p = 0.021). In a similar study, Greenberg and colleagues 40 obtained a median time to relapse of 178 days in the 6 mg group, 124 days in the 3 mg group, and 39 days in the placebo group (p = 0.027). Oral budesonide 6 mg/day offered no benefit in prevention of endoscopic recurrence after surgery for ileal/ileocaecal fibrostenotic CD, but decreased the recurrence rate in patients who had undergone surgery for disease activity (recurrence rate 32% versus 65% respectively, p = 0.047). 41 Cortot and colleagues 42 used budesonide to switch patients with steroid dependent CD from systemic steroids. Introduction of budesonide during the steroid tapering decreased steroid related side effects and maintained remission.
Adverse events
Budesonide CIR 9 mg/day induced significantly less corticosteroid associated side effects compared to prednisolone. Median plasma cortisol concentrations in patients treated with budesonide 9 mg and 15 mg were reduced below baseline after two weeks and remained low throughout the study; budesonide 3 mg, however, did not influence the adrenocortical axis. Budesonide 9 mg/day affected plasma cortisol concentrations less than prednisolone 40 mg/day. In the Rutgeerts and Campieri studies, plasma cortisol concentrations were significantly lower in the prednisolone group than in the budesonide group after two, four, and eight weeks. The proportion of patients with plasma cortisol concentrations below the normal range was significantly higher in the prednisolone group at all times.
SUMMARY
The role of salicylates is well established in UC, but recent evidence has challenged it in CD, mainly in maintenance of remission and prevention of postoperative relapse. New steroids are a valid alternative to old steroids and salicylates in the treatment of active UC and CD, but are not effective in maintenance of remission.
In the past two decades, salicylates have been established in a number of controlled clinical trials as the main drug for treatment of UC. With the aim of achieving the same efficacy of SSP but without its major side effects, various preparations of new salicylates (such as mesalazine, olsalazine, and balsalazide) have been formulated, in order to assure targeted release, minor discomfort, and safety in use. New topical formulations have improved the choice, depending on the extent of disease. In treatment of CD the role of new salicylates is more complex. Mesalazine has been effective in the treatment of mild to moderate active CD, but failed to maintain remission. Its role in the prevention of postoperative relapse has recently been challenged and the discussion is still open.
Glucocorticoids are the main therapy in active UC and CD, but two open questions concern steroid dependence and steroid related side effects. The new steroids such as budesonide and BDP are characterised by high topical efficacy, because of rapid uptake by mucosal tissue and high GCS affinity, while minimising the risk of systemic effects by virtue of efficient hepatic inactivation. These features help to ensure that the products are well tolerated and patient compliance is maintained. Several studies have shown that topical budesonide or BDP are as effective in the treatment of distal UC as traditional steroids, with no effects on cortisol production. When administered as an oral, controlled release formulation, budesonide 9 mg is as effective as prednisolone 40 mg and more effective than mesalazine 4 g in active, mild to moderate CD. Moreover, budesonide is useful in steroid dependent CD. Unfortunately, it prolonged the time to relapse but failed to maintain remission in CD and prevent postoperative relapse. These studies, nevertheless, showed that the drug is safe in long term treatment.
